PMID- 17686178
OWN - NLM
STAT- MEDLINE
DCOM- 20081208
LR  - 20181113
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 5
DP  - 2007 Aug 8
TI  - Semi-allogeneic vaccine for T-cell lymphoma.
PG  - 39
AB  - BACKGROUND: Experimental results from studies with inbred mice and their 
      syngeneic tumors indicated that the inoculation of semi-allogeneic cell hybrids 
      (derived from the fusion between syngeneic tumor cells and an allogeneic cell 
      line) protects the animal host from a subsequent lethal challenge with unmodified 
      syngeneic tumor cells. METHODS: Semi-allogeneic somatic cell hybrids were 
      generated by the fusion of EL-4 T lymphoma cells (H-2b) and BALB/c-derived renal 
      adenocarcinoma RAG cells (H-2d). Cell hybrids were injected intra-peritoneally 
      (i.p.) in C57BL/6 mice (H-2b) before challenging the mice with a tumorigenic dose 
      of EL-4 cells. RESULTS: Semi-allogeneic tumor cell hybrids could not form a tumor 
      in the animal host because they expressed allogeneic determinants (H-2d) and were 
      rejected as a transplant. However, they conferred protection against a 
      tumorigenic challenge of EL-4 cells compared to control mice that were 
      mock-vaccinated with i.p.-injected phosphate-buffered saline (PBS) and in which 
      EL-4 lymphomas grew rapidly to a large size in the peritoneal cavity. Screening 
      of spleen-derived RNA by means of focused microarray technology revealed 
      up-regulation of genes involved in the Th-1-type immune response and in the 
      activation of dendritic antigen-presenting cells (APC). CONCLUSION: The results 
      of our studies are entirely consistent with the concept that CD80- and 
      CD86-expressing APC play a central role in mediating the immune protection 
      induced by semi-allogeneic vaccines by activating a Th-1 response and instructing 
      T cells responsible for killing autologous tumor cells.
FAU - Yu, Jin
AU  - Yu J
AD  - Department of Radiation Oncology, Medical University of South Carolina, 
      Charleston, SC, USA. yujin@musc.edu
FAU - Kindy, Mark S
AU  - Kindy MS
FAU - Gattoni-Celli, Sebastiano
AU  - Gattoni-Celli S
LA  - eng
PT  - Journal Article
DEP - 20070808
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Cancer Vaccines)
RN  - TDQ283MPCW (Eosine Yellowish-(YS))
RN  - YKM8PY2Z55 (Hematoxylin)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*immunology
MH  - Cell Line, Tumor
MH  - Dendritic Cells/immunology
MH  - Eosine Yellowish-(YS)
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, Neoplasm
MH  - Hematoxylin
MH  - Lymphoma, T-Cell/genetics/*immunology/*prevention & control
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Oligonucleotide Array Sequence Analysis
MH  - Spleen/immunology
PMC - PMC1971246
EDAT- 2007/08/10 09:00
MHDA- 2008/12/17 09:00
PMCR- 2007/08/08
CRDT- 2007/08/10 09:00
PHST- 2007/05/29 00:00 [received]
PHST- 2007/08/08 00:00 [accepted]
PHST- 2007/08/10 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2007/08/10 09:00 [entrez]
PHST- 2007/08/08 00:00 [pmc-release]
AID - 1479-5876-5-39 [pii]
AID - 10.1186/1479-5876-5-39 [doi]
PST - epublish
SO  - J Transl Med. 2007 Aug 8;5:39. doi: 10.1186/1479-5876-5-39.